
CNTX Stock Forecast & Price Target
CNTX Analyst Ratings
Bulls say
Context Therapeutics is expected to see major success in the biopharmaceutical industry due to its promising preclinical program and pipeline of therapies focused on treating hormone-dependent cancers. The company's clinical execution story, with two Phase 1a bispecific readouts expected in 2026, along with a third program moving towards the clinic, creates a strong momentum for Context Therapeutics. The company's strong financial position, with $76.9M in cash and cash equivalents as of September 30, 2025, provides a sufficient runway for operations until mid-2027, allowing investors to focus on data from upcoming clinical trials. The company's innovative approach utilizing bispecific antibody technology and pH-dependent binding is expected to result in quick proof-of-concept for its programs, potentially attracting potential partners and driving investor interest.
Bears say
Context Therapeutics is a biopharmaceutical company with a negative outlook due to potential risks in clinical trials, financial concerns, and competition in the market. Despite a promising pipeline targeting hormone-dependent cancers, the company's early stage development and recent update on its Phase 1a trial for CTIM-76 raise concerns about its ability to achieve proof-of-concept and attract potential partners or investors. Additionally, the update on CT-95's dosing and target exposure suggest potential delays in reaching milestones.
This aggregate rating is based on analysts' research of Context Therapeutics LLC and is not a guaranteed prediction by Public.com or investment advice.
CNTX Analyst Forecast & Price Prediction
Start investing in CNTX
Order type
Buy in
Order amount
Est. shares
0 shares